reference/21495648

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21495648

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't
endingPage	730
issn	0732-183X 1527-7755
issueIdentifier	6
pageRange	724-730
publicationName	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
startingPage	724
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_448c3d7a8b95445db230c0de0b6d375a
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_84c5d41ff20d869943d0631610ee9fc4 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_7b4da5a6b145f80205d7d0abc6b007ef http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_f44e02fcf9fa27484f2fa88838529c69
bibliographicCitation	Balar AV, Apolo AB, Ostrovnaya I, Mironov S, Iasonos A, Trout A, Regazzi AM, Garcia-Grossman IR, Gallagher DJ, Milowsky MI, Bajorin DF. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol. 2013 Feb 20;31(6):724–30. PMID: 23341513; PMCID: PMC3574268.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_70b214608591fdf0cdd8c92d1f888370 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1b1ee58ce2d2d2d284e5c94f5a73ef35 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6dc6adea464bdbd65cb05feecff39522 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_90b2562f3739e10669ce4514dc37769e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_454961634dfef4952090a66285303991 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a0f84f640ef66bec1fe28e1a86c0b427 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_106a4dc3b01e4f019a7a44d92f55fd16 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_efe43c1dc28bbc10926a549713543036 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ee5f43452466d1ae7e020ae09edf651e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f68d247e3d57215bf54baeda27ba863e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9f5650424726de472671d0ef14cf931f
date	2013-02-20^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1200/jco.2012.42.5215 https://pubmed.ncbi.nlm.nih.gov/23341513 https://pubmed.ncbi.nlm.nih.gov/PMC3574268
isPartOf	https://portal.issn.org/resource/ISSN/1527-7755 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5023 https://portal.issn.org/resource/ISSN/0732-183X
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer
discusses	http://id.nlm.nih.gov/mesh/M0443627 http://id.nlm.nih.gov/mesh/M0024707 http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M000754277 http://id.nlm.nih.gov/mesh/M0005997
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D014571Q000188 http://id.nlm.nih.gov/mesh/D019459Q000187
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D003248Q000139 http://id.nlm.nih.gov/mesh/D005221Q000139 http://id.nlm.nih.gov/mesh/D019459Q000473 http://id.nlm.nih.gov/mesh/D003841Q000009 http://id.nlm.nih.gov/mesh/D003841Q000008 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000093542 http://id.nlm.nih.gov/mesh/D009362 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D003841Q000031 http://id.nlm.nih.gov/mesh/D061067Q000008 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D061067Q000009 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D009503Q000139 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000068258 http://id.nlm.nih.gov/mesh/D014571Q000473 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D016190Q000009 http://id.nlm.nih.gov/mesh/D016190Q000008 http://id.nlm.nih.gov/mesh/D053208 http://id.nlm.nih.gov/mesh/D000971Q000009
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID588 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60750 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9548 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID426756 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9410 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9022 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6640 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10516 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5702198

Showing number of triples: 1 to 82 of 82.